Latest news

• Cosentyx, Entresto drive topline growth for Novartis in Q4

  Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and

• Novartis highlights emerging assets and late-stage pipeline at R&D day

  It also has plans to expand wet AMD therapy  Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments  Piqray (alpelisib) and  Kisqali(ribociclib) into additional indications to help drive growth.

• Novartis raises 2019 guidance as new products gather speed

  and Piqray (alpelisib) for breast cancer – that both have blockbuster sales potential.

• FDA clears Novartis’ new breast cancer drug Piqray

  The approval is for Piqray (alpelisib formerly BYL719) alongside fulvestrant, a combination that almost doubled progression-free survival (PFS) compared to fulvestrant alone in the SOLAR-1 study. ... Trials are also in play comparing alpelisib and

• Novartis sees five new $1bn-plus launches in next two years

  Novartis’ near-term pipeline has plenty more to deliver this year, including a possible approval for new breast cancer drug alpelisib (BYL719), which has bucked the trend of disappointing clinical results